Abstract
Combination immunotherapy with an anti-PD-1 inhibitor and an anti-CTLA-4 inhibitor is used as first-line therapy in metastatic renal cell carcinoma (mRCC). While providing the benefit of a certain population of long-term responders, the frequency of immune-related adverse events (irAEs) is known to be high with the combination therapy. Thus, predictive biomarkers of irAEs could help guide treatment strategies.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
